Company: BWAY
Filing Date: 2025-05-01
Form Type: 424B3
Source: 0001171843-25-002668
Chunk: 1

Company: Brainsway Ltd.
Filing Date: 2025-05-01
Form: 424B3
Chunk 1
---
ed ADSs. We will bear all costs, expenses
and fees in connection with the registration of the Ordinary Shares and the Offered ADSs. For additional information on the methods of
sale that may be used by the selling shareholder, see “Plan of Distribution” beginning on page 15 of this prospectus.

Our Ordinary Shares are traded on the Tel Aviv Stock
Exchange (the “TASE”), and the ADSs are traded on the Nasdaq Global Market under the symbol “BWAY.” The last
reported sale price for the ADSs on April 29, 2025 as quoted on the Nasdaq Global Market was $8.89 per ADS, and the last reported sale
price for our Ordinary Shares on April 29, 2025 as quoted on the TASE was NIS 16.50 per Ordinary Share, or $4.55 per Ordinary Share (based
on the exchange rate reported by the Bank of Israel for such date).

We are a “foreign private
issuer” under applicable Securities and Exchange Commission (“SEC”) rules, and will be subject to reduced public company
reporting requirements for this prospectus and future filings. See “Prospectus Summary — Implications of Being a Foreign Private
Issuer.”

Investing in these securities involves a high degree of risk. Please carefully consider the risks discussed in this prospectus under “Risk Factors” beginning on page 4 and the “Risk Factors” in “Item 3: Key Information- Risk Factors” of our most recent Annual Report on Form 20-F incorporated by reference in this prospectus, any applicable prospectus supplement and in any free writing prospectus we have authorized for use in connection with a specific offering, and under similar headings in the other documents incorporated by reference into this prospectus, for a discussion of the factors you should consider carefully before deciding to purchase these securities.

Neither the Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense.

<div align='center'>The date of this prospectus is
April 30, 2025.

TABLE OF CONTENTS</div>

Page

| ABOUT THIS PROSPECTUS                           |  i |
| PROSPECTUS SUMMARY.                             |  1 |
| RISK FACTORS                                    |  4 |
| FORWARD-LOOKING STATEMENTS                      |  4 |
| CAPITALIZATION                                  |  6 |
| USE OF